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Short Communication
Vaccination is arguably the most crucial protection strategy
available against infectious agents. The World Health Organisation
(WHO) estimates immunisations against the pathogens diphtheria,
pertussis, tetanus, and measles avert 2-3 million deaths every year [1].
However, despite our advanced knowledge and the availability of
highly effective vaccines against many diseases, several infectious
agents, such as influenza A virus, continue to be a major scientific
challenge. Accumulating reports of human infection with Avian
influenza strains H5N6, H7N9, H9N2, and the highly pathogenic
H5N1 illustrate a major public health concern. Current seasonal
influenza vaccines will not protect against newly emerging pandemic
strains if they acquire efficient human-human transmission and
disseminate through the population. In fact, commercially available
inactivated vaccines against influenza A virus confer strain specific
antibody-mediated protection only, and require annual reformulation
to accommodate for the frequent emergence of antigenically distinct
strains. In addition, the WHO recommendation for flu vaccine
formulation is based on an educated-guess approach guided by WHO
surveillance of recent virus activity. Our recent encounter with the
pandemic pH1N1 influenza A virus in 2009 illustrates the inability of
current flu vaccination strategies to control novel emerging and
pandemic strains. The time required to manufacture new vaccines
based on newly arising strains similarly limits the effectiveness of
current strategies. These shortcomings highlight the need for a new
approach to develop flu vaccines that are capable of providing
protection against emerging strains.
We have previously reported the use of gamma-irradiation to
inactivate Influenza A virus for vaccine purposes, and illustrated the
ability of this vaccine (γ-Flu) to induce cross-protective immunity
against both seasonal and pandemic virus strains, including Avian
H5N1 [2]. Importantly, we demonstrated the ability of γ-Flu to induce
cross-reactive cytotoxic T-cell responses [3] as well as strain-specific
neutralising antibody responses [4]. We have recently published the
possibility of using irradiation doses as high as 50 kGy to inactivate
influenza A virus without severely affecting vaccine immunogenicity
[5]. The possible use of high irradiation dose would allow inclusion of
highly pathogenic Influenza A strains in future vaccine formulations.
This approach could also be used to develop a contingency plan against
future pandemics, including the possibility of vaccine stockpiling as we
have previously illustrated the stability of freeze-dried γ-Flu
formulations [6].
It is generally accepted that inactivation of microorganisms using γ-
irradiation follows physical laws, including the concept of an
‘exponential law’, whereby there always exists a finite probability that
an organism may survive irrespective of the irradiation dose used [7].
To ensure sterility of irradiated materials, the concept of Sterility
Assurance Level (SAL) has been adopted, which refers to the
probability of micro-organisms surviving the irradiation process [8].
SAL is arbitrarily determined and a value of 10-3 or 10-6 (one in a
thousand or a million chance of having live microorganisms in any one
unit) has been widely accepted. To estimate the irradiation dose
required to achieve a chosen SAL, a mathematical concept based on
the decimal reduction value (the D10 value) has been used [9]. The D10
value refers to the irradiation dose required to inactivate 90% of the
microbial population (i.e. a dose causing a single log10 reduction). In
fact, while a SAL value of 10-3 or 10-6 has been widely accepted,
exposure to higher radiation doses that exceed the critical parameter of
SAL can be considered as an effective approach to further reduce the
probability of any live pathogens persisting after irradiation [10]. In
addition, an exposure to an irradiation dose of 50 kGy has been largely
considered as mandatory for treatment of products suspected of being
contaminated with highly pathogenic agents (e.g. H5N1 Influenza,
Ebola) [9]. However, an exposure to high irradiation dose may be
associated with extensive damage to antigenic structure, consequently
affecting vaccine efficacy.
It is important to emphasize that the “radiation sensitivity” of a
pathogen is mainly related to damage to nucleic acid structure (for
example, single- or double-strand breaks, cross-linkages, and other
nucleotide damage). In addition, gamma-irradiation has been shown
to be associated with protein damage [11], including fragmentation
due to breakage of covalent bonds within the polypeptide chain [12].
This is illustrated by excessive damage to Murine Norovirus 1
(MNV-1) capsid protein VP1 following irradiation with increased
doses of gamma-rays at room temperature [13]. Importantly,
modulating irradiation conditions could help control the extent of the
structural damage. Our recently published data illustrate that
irradiation of influenza A virus on dry ice is associated with limited
structural damage compared to irradiation at room temperature [5].
Our data show that influenza A virus irradiated at room temperature
suffered significantly greater loss of surface protein functionality and
increased damage to virion integrity, leading to reduced vaccine
efficacy. In contrast, irradiation on dry-ice aided preservation of virion
integrity and allowed for significant maintenance of antigenic epitopes.
Thus, our data illustrated the high immunogenicity of materials
irradiated on dry-ice, despite the exposure to 50 kGy. Achieving
vaccine sterility without damaging antigenic epitopes is essential for
future development of highly effective vaccines. Interestingly,
irradiation of frozen materials (at -80°C) has also been reported
previously for inactivation of Venezuelan Equine Encephalitis Virus
(VEEV) and Eastern Equine Encephalitis Virus (EEEV) for vaccine
purposes using high doses of irradiation. VEEV irradiated with 50 kGy
was reported to induce protection against subcutaneous and aerosol
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challenge with live virus in mice [14]. In addition, EEEV irradiated
with 100 kGy was shown to induce both neutralising antibody
responses and protection against aerosol challenge [15]. These studies
support our early proposal regarding the suitability of gamma-
irradiation to inactivate highly infectious agents for vaccine purposes
[7]. A combination of high irradiation dose and a controlled
irradiation temperature appeared to be sufficient to minimise
structural damage, and consequently ensures vaccine safety and
efficacy. This technique may be applied to pathogens against which
vaccine design has been inherently complicated. Recent reports of
phase I human clinical trials of an attenuated HIV vaccine doubly-
treated with gamma-irradiation (30 kGy) and chemical inactivation
(Trial Registration: Clinical Trials NCT01546818) illustrate the
effectiveness of gamma-irradiation as a clinically relevant vaccine
inactivation method [16].
Overall, gamma-irradiation represents a very promising approach
for development of highly effective vaccines. The high immunogenicity
of materials irradiated with 50 kGy considerably expands the list of
pathogens suitable for irradiation treatment for vaccine purposes. In
addition, irradiation may be used to inactivate existing live attenuated
vaccines to enhance safety and to allow for administration of an
increased antigen dose without compromising efficacy.
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